CytoMed Therapeutics Limited

NasdaqCM GDTC

CytoMed Therapeutics Limited EBITDA Margin for the year ending December 31, 2023: -1,011.10%

CytoMed Therapeutics Limited EBITDA Margin is -1,011.10% for the year ending December 31, 2023, a -146.10% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

CytoMed Therapeutics Limited EBITDA Margin for the year ending December 31, 2022 was -410.85%, a 70.90% change year over year.
CytoMed Therapeutics Limited EBITDA Margin for the year ending December 31, 2021 was -1,412.07%, a 12.87% change year over year.
CytoMed Therapeutics Limited EBITDA Margin for the year ending December 31, 2020 was -1,620.57%.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqCM: GDTC

CytoMed Therapeutics Limited

CEO	Mr. Chee Kong Choo
IPO Date	April 14, 2023
Location	Singapore
Headquarters	1 Commonwealth Lane, No. 08-22
Employees	28
Sector	Healthcare
Industries Biotechnology 3D Printing Robotics

Description

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.

Key trends

Past 5 years